These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 26319429)

  • 1. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
    Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK
    HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
    Busch CJ; Laban S; Knecht R; Hoffmann TK
    HNO; 2016 Oct; 64(10):708-16. PubMed ID: 27604282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Treatment Options in Head and Neck Cancer.
    Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
    Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
    Gliese A; Busch CJ; Knecht R
    HNO; 2016 Oct; 64(10):717-22. PubMed ID: 27624903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy for HNSCC : Quo vadis?].
    Döscher J; Busch CJ; Schuler PJ; Laban S
    HNO; 2016 Oct; 64(10):700-7. PubMed ID: 27624904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
    Schuler PJ; Doescher JC; Laban S; Hoffmann TK
    HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
    Bauman JE; Cohen E; Ferris RL; Adelstein DJ; Brizel DM; Ridge JA; O'Sullivan B; Burtness BA; Butterfield LH; Carson WE; Disis ML; Fox BA; Gajewski TF; Gillison ML; Hodge JW; Le QT; Raben D; Strome SE; Lynn J; Malik S
    Cancer; 2017 Apr; 123(7):1259-1271. PubMed ID: 27906454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
    Doescher J; Busch CJ; Wollenberg B; Dietz A; Würdemann N; Schuler P; Hoffmann TK; Laban S
    HNO; 2019 Dec; 67(12):905-911. PubMed ID: 31612261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy highlights of the ASCO annual meeting 2018 for head and neck cancers].
    Laban S; Doescher J; Busch CJ; Wollenberg B; Dietz A; Würdemann N; Schuler PJ; Hoffmann TK
    HNO; 2018 Dec; 66(12):880-887. PubMed ID: 30402813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Main results of studies on primary therapy of head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].
    Gliese A; Busch CJ; Knecht R
    HNO; 2014 Nov; 62(11):781-6. PubMed ID: 25274201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the ASCO Meeting 2016].
    Bußmann L; Busch CJ; Knecht R
    HNO; 2016 Oct; 64(10):723-30. PubMed ID: 27604281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Schoppy DW; Sunwoo JB
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
    Economopoulou P; Kotsantis I; Psyrri A
    Curr Treat Options Oncol; 2016 Aug; 17(8):40. PubMed ID: 27315066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.
    Outh-Gauer S; Alt M; Le Tourneau C; Augustin J; Broudin C; Gasne C; Denize T; Mirghani H; Fabre E; Ménard M; Scotte F; Tartour E; Badoual C
    Cancer Treat Rev; 2018 Apr; 65():54-64. PubMed ID: 29547766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases: Highlights of the ASCO Meeting 2015].
    Bußmann L; Busch CJ; Knecht R
    HNO; 2015 Sep; 63(9):620-4. PubMed ID: 26319430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
    Huang LL; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.